Ge Long Hui·2025-10-24 09:17Core Viewpoint - China Resources Pharmaceutical (03320.HK) reported a total revenue of RMB 4.766 billion for Dong'e Ejiao for the nine months ending September 30, 2025, representing a year-on-year growth of 4.41% [1] - The net profit for the same period was RMB 1.277 billion, reflecting a year-on-year increase of 10.77% [1] - As of the announcement date, the company directly holds 10.19% of Dong'e Ejiao's shares and approximately 23.50% through its non-wholly owned subsidiary, indicating a total effective control of about 23.50% [1] Financial Performance - Total revenue for Dong'e Ejiao reached RMB 4.766 billion, up 4.41% year-on-year [1] - Net profit amounted to RMB 1.277 billion, showing a growth of 10.77% compared to the previous year [1] - The cash and cash equivalents at the end of the period were RMB 3.238 billion [1] Ownership Structure - The company directly holds 10.19% of Dong'e Ejiao [1] - Through its subsidiary, China Resources Dong'e Ejiao Co., Ltd., the company holds approximately 23.50% [1] - The total effective control of Dong'e Ejiao by the group is approximately 23.50%, classified as a subsidiary [1]